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Hypertension, is a major modifiable risk factor for renal, cardiovascular and cerebrovascular disease 
and a leading underlying cause of global mortality and morbidity(1). Incremental advances in our 
understanding of blood pressure have highlighted its complex pathophysiology, whereby genetic 
and environmental factors combine with a plethora of physiological pathways and mechanisms to 
ultimately yield the phenotype. While epidemiological studies have improved our understanding of 
environmental factors in relation to blood pressure, especially with regards to diet and exercise, the 
exact role of genetics in this setting has been challenging to tease apart from the shared environment 
often found in families and communities(2).   
In this issue of the European Heart Journal, Niiranen et al. provide an intriguing insight into this 
topic. Using blood pressure data systematically acquired across three generations of the 
Framingham Heart Study, the authors showed that higher blood pressure, not only in parents, but 
also in grandparents, is associated with risk of the same condition in the third generation 
individuals. Specifically, a family history of hypertension developed before 55 years of age 
represents the strongest risk factor for high blood pressure in the offspring, independently from 
several measured environmental factors known to influence the risk of hypertension, including 
levels of physical activity, dietary sodium and alcohol intake. Importantly, the fact that 
grandparental hypertension confers risk in grandchildren and that only 10% of the grandchildren 
had last reported living in Framingham, suggests that the impact of shared environment here is 
likely to be low, making the genetic effect perhaps more apparent. There are of course limitations in 
the approach which the authors describe, but overall these data support the concept of genetic 
predisposition to hypertension. 
Understanding these genetic factors has been a key challenge facing investigators over time.  Twin 
and family based studies have indicated that as much as 30%-50% of the variance in blood pressure 
readings may be heritable, while a growing list of rare disorders have led to the identification of 
clear and causal Mendelian mutations(3). At a population level however, the smooth Gaussian 
distribution of blood pressure suggests that these mutations are unlikely to play a major role and 
that, if anything, multiple genetic effects, each of a small size, are likely be contributing or adding 
susceptibly to high blood pressure levels. With the advent of the genomic era, it is now generally 
accepted that the most common form of hypertension is a complex trait with a polygenic basis and 
environmental influences that may also exert effects through epigenetic changes which could even 
be transmitted across generations(3-5).   
The completion of the Human Genome Project and HapMap initiatives yielded a multitude of 
genome wide association studies (GWAS) that have sought to discover these common genetic 
variants. From the early and negative GWAS for hypertension within the Wellcome Trust Case 
Control Consortium(6) to the more recent reports by Warren et al.(7) and Hoffman et al(8), 
hundreds of genetic variants have been associated with risk of high blood pressure, as well as other 
traits such as coronary artery disease, for which hypertension may be on the causal pathway. 
Although the contribution of each SNP to systolic and diastolic blood pressure values is typically 
very small(9), when combined together their cumulative impact is more revealing.  For example, in 
the recent report by Warren et al. combination of multiple SNPs into a risk score, accounted for a 
difference in systolic blood pressure values up to 10mmHg between individuals(7). Despite this, the 
combined contribution of these multiple genetic variants to heritability estimates remains lower than 
expected leading to questions about “missing” heritability. This however is not unique to 
hypertension and is seen in other complex traits such as coronary disease(10). Although it is 
expected that many more yet undiscovered loci will contribute to explain the missing heritability, it 
has been postulated that, at least in part, this discordance could be also related to an over-estimation 
of initial hereditary estimates as well as phenotypic pleiotropy.   
Phenotype is of course as critical as genotype in these studies.  As with other traits, premature onset 
of a condition is often considered to be more specific and genetically driven than environment or 
lifestyle factors. This is also supported by the findings from Niiranen et al, who report that early 
(onset before 55 years) rather than late onset of hypertension in first and second degree parents is a 
stronger predictor of the risk of elevated blood pressures values in offspring. From about 50-55 
years, values of systolic blood pressure are known to increase while diastolic blood pressure 
decreases due to a generalised process of vascular ageing which results from poor ventricular 
coupling and increased arterial stiffness secondary to arteriosclerosis(11). The risk of elevated 
values of blood pressure and cardiovascular disease observed after 55 years of age, therefore, are 
likely to reflect not only genetic influences affecting specific pathways involved in the pathogenesis 
of the disease, but also the contribution of gene variants regulating the evolution of cellular 
ageing(12). This could explain the persistence of a strong association between early onset of blood 
pressure in grandparents and risk of hypertension in grandchildren, even when the association was 
adjusted for the number of parents and grandparents with late-onset hypertension were included in 
the same model.  
Genetic discoveries from GWAS now awaits further inquiry to ascertain whether new mechanisms 
and pathways for hypertension exist with possibly novel therapeutic targets.  The key question 
remains whether we can use this genetic information directly to improve our patient’s care.  
Currently, the majority of interventions for hypertension are initiated later in life when blood 
pressure values are already elevated, vessels stiffened or end organ damage initiated.  We then 
follow the general approach of prescribing the same sequence of anti-hypertensive drugs for all 
patients with the disease, based on specific algorithms endorsed by professional societies. Although 
this approach has the advantage of simplifying treatment decisions, it does not take into account the 
variable contribution of different biological pathways involved in the pathogenesis of hypertension 
in any given individual.  Screening the human genome for known variants associated with increased 
risk of hypertension and combination of this information into genetic risk scores, could provide not 
only information on an individual’s risk of developing hypertension but also perhaps which 
pathways are primarily responsible. This approach could lead to more effective prevention of 
cardiovascular disease based on: a) earlier identification of subjects at risk before development of 
the phenotype, b) implementation of aggressive and perhaps targeted lifestyle interventions and c) a 
more rational and targeted selection of cardiovascular drugs that are likely to be effective and safe 
for that individual. These concepts are at the foundation of “precision medicine”, which is based on 
identifying pre-symptomatic, high-risk patients with distinct mechanisms of disease and particular 
responses to treatments(13). As heart disease and hypertension are highly prevalent and have 
relatively large effects on life expectancy, precision medicine applied to these diseases might lead 
much higher to public health and economical benefits than precision medicine initiatives aimed at 
reducing other common diseases, including diabetes, cancer, stroke and lung diseases(14). Although 
this is an attractive prospective, the value of DNA sequencing for precision medicine in 
hypertension or indeed many other complex traits requires additional important steps before its 
application to a clinical setting can be considered.  
The paper by Niiranen et al has leveraged the invaluable information on family structure and rich 
phenotype data from the Framingham cohort to shed some unique insights into transgenerational 
blood pressure risk.  While it may seem a relatively “low tech” approach, the authors have 
highlighted that simply asking patients about a family history of early onset hypertension in parents 
and possibly grandparents could provide the clinician with a simple instrument to identify young 
patients at potentially higher risk of hypertension due to a shared genetic and environmental 
background. These individuals, at the very least, should be offered aggressive lifestyle modification 
and closer monitoring for development of high blood pressure. Perhaps a useful intermediate step 
while we await the promise of precision medicine. 
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